Tomoki Todo
MD PhD
Professor
👥Biography 个人简介
Tomoki Todo at Tokyo developed G47delta — a triple-mutated oncolytic herpes simplex virus engineered for enhanced tumor selectivity and safety — which received conditional approval in Japan for recurrent glioblastoma in 2021, the first oncolytic virus approval for brain cancer. His development of progressively refined engineered HSV-1 oncolytic vectors and their clinical translation represents an important contribution to oncolytic virotherapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Tomoki Todo 的研究动态
Follow Tomoki Todo's research updates
留下邮箱，当我们发布与 Tomoki Todo（University of Tokyo）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment